Updated Date: Tue, 04 Jan 2022 00:00:00 EST
Category: Uncategorized
JPM 2022: Amgen dials up biosimilar ambitions, with at least $4B in expected sales by 2030 fkansteiner Tue, […]
JPM 2022: Sanofi has designs on creating Big Pharma’s ‘strongest’ immunology franchise, CFO says esagonowsky Tue, 01/11/2022 – […]
JPM 2022: AbbVie adjusts 2025 individual sales projections for Rinvoq and Skyrizi but not their combined total of […]
Researchers at Uppsala University have used AI to develop a new method to study brain cancer. The method […]
At the first sign of cognitive trouble, people often worry Alzheimer’s disease is forthcoming. But poor cognition can […]
Two people who had serious diseases but not terminal prognoses have ended their lives legally in Colombia with […]
JPM22, Day 2: Teva’s opioid litigation, Roche’s Tecentriq ambitions and more esagonowsky Tue, 01/11/2022 – 08:17
JPM 2022: Bluebird CEO sees ‘unfinished business’ with Zynteglo in Europe, but scale-up needed first
JPM 2022: Bluebird CEO sees ‘unfinished business’ with Zynteglo in Europe, but scale-up needed first aarmstrong Tue, 01/11/2022 […]
